Masahiro Natsuaki Selected Research

Masahiro Natsuaki Research Topics

Disease

43	Myocardial Infarction 05/2024 - 02/2010
39	Thrombosis (Thrombus) 05/2024 - 09/2012
39	Hemorrhage 05/2024 - 05/2012
23	Stroke (Strokes) 11/2023 - 01/2011
13	Coronary Artery Disease (Coronary Atherosclerosis) 11/2023 - 06/2012
12	Acute Coronary Syndrome 05/2024 - 01/2020
6	Ischemic Stroke 05/2024 - 01/2018
5	ST Elevation Myocardial Infarction 01/2024 - 04/2013
3	Neoplasms (Cancer) 11/2023 - 01/2022
3	Chronic Renal Insufficiency 02/2023 - 12/2012
3	Atrial Fibrillation 01/2020 - 07/2014
3	Death (Near-Death Experience) 01/2018 - 09/2013
2	Body Weight (Weight, Body) 01/2022 - 01/2020
2	Ischemia 01/2020 - 10/2016
2	Unstable Angina 01/2020 - 01/2019
2	Hemorrhagic Stroke 11/2019 - 01/2019
2	Pathologic Constriction (Stenosis) 01/2019 - 01/2018
1	Mitral Valve Insufficiency (Mitral Regurgitation) 04/2024
1	Left Ventricular Dysfunction 04/2024
1	Liver Cirrhosis (Hepatic Cirrhosis) 11/2023
1	Bites and Stings (Sting) 07/2022
1	Hypersensitivity (Allergy) 07/2022
1	Heart Failure 01/2021
1	Inflammation (Inflammations) 01/2020
1	Type 2 Diabetes Mellitus (MODY) 12/2019
1	Intracranial Hemorrhages (Intracranial Hemorrhage) 11/2019
1	Anemia 11/2019
1	AIDS-Related Complex (ARC) 11/2019
1	Diabetes Mellitus 04/2018
1	Chronic Obstructive Pulmonary Disease (COPD) 09/2013
1	Hypertension (High Blood Pressure) 09/2013
1	Rupture 02/2010

Drug/Important Bio-Agent (IBA)

17	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 05/2024 - 07/2014
10	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 11/2023 - 01/2012
9	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2024 - 01/2015
6	Everolimus FDA Link 05/2024 - 03/2017
6	Clopidogrel (Plavix)FDA Link 10/2023 - 01/2019
5	Streptokinase FDA Link 01/2022 - 01/2018
5	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 01/2018
4	BESIBA 08/2023 - 07/2013
4	PolymersIBA 08/2023 - 03/2017
4	Sirolimus (Rapamycin)FDA Link 01/2018 - 06/2012
4	omega-Chloroacetophenone (Mace)IBA 12/2014 - 01/2011
3	CobaltIBA 05/2024 - 01/2020
3	N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA 05/2024 - 11/2023
3	ChromiumIBA 05/2024 - 01/2020
3	Serum AlbuminIBA 04/2024 - 12/2021
2	Prasugrel Hydrochloride FDA Link 05/2024 - 11/2023
2	pitavastatin (itavastatin)FDA Link 01/2023 - 01/2022
2	Hemoglobins (Hemoglobin)IBA 01/2022 - 11/2019
2	MetalsIBA 12/2015 - 04/2014
2	thienopyridineIBA 11/2015 - 06/2012
1	LDL CholesterolIBA 01/2023
1	oxidized low density lipoproteinIBA 01/2023
1	AlbuminsIBA 01/2022
1	LipidsIBA 01/2022
1	Insulin (Novolin)FDA Link 01/2020
1	AngiopoietinsIBA 10/2016
1	Coenzyme A (CoA)IBA 10/2016
1	GlyceraldehydeIBA 10/2016
1	Advanced Glycation End ProductsIBA 10/2016
1	Dihydrotachysterol (AT 10)IBA 12/2015
1	ThienopyridinesIBA 01/2015
1	APTIBA 01/2015
1	AnticoagulantsIBA 07/2014
1	Angiotensin Receptor AntagonistsIBA 09/2013
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 09/2013
1	Therapeutic UsesIBA 12/2012
1	Ticlopidine (Ticlid)FDA LinkGeneric 06/2012

Therapy/Procedure

43	Stents 05/2024 - 06/2012
36	Percutaneous Coronary Intervention 01/2024 - 02/2010
25	Therapeutics 05/2024 - 06/2012
19	Drug-Eluting Stents 08/2023 - 11/2015
7	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/2022 - 10/2012
1	Polypharmacy 09/2023
1	Duration of Therapy 04/2022
1	Aftercare (After-Treatment) 01/2021
1	Renal Dialysis (Hemodialysis) 01/2019
1	Punctures 05/2012
1	Cardiopulmonary Resuscitation (CPR) 02/2010